All CEL files obtained from HuGene20st microarrays (Affymetrix) are available in GEO repository (GSE93945).

Introduction {#sec001}
============

Previous research has identified mechanisms triggered with the practice of moderate exercise that yield beneficial effects on health, specially on cardiovascular disease \[[@pone.0180322.ref001]\]. These effects may be explained due to the adaptation of many organs to cope with required musculoskeletal performance \[[@pone.0180322.ref002]\]. However, health benefits for the case of extreme endurance exercise remain unclear \[[@pone.0180322.ref003],[@pone.0180322.ref004]\].

Ultra-marathon trails (UMTs) could be considered as extreme endurance exercise since their running events should be longer than the traditional marathon (42.195 km). Typically, they are run through a mountainous terrain with a considerable accumulated altitude change. Due to their high physical and psychological demand, UMTs are identified as an ideal sport for investigating a wide range of physiological responses \[[@pone.0180322.ref005]\]. These competitions show a growing popularity as indicated by the, approximately, sevenfold increase in the number of finishers of 100km worldwide ultra-marathons between 1998 and 2011 \[[@pone.0180322.ref006]\]. In parallel, the amount of scientific contributions focusing on UMT interventions has risen. They cover a varied range of perspectives: some authors detected reactive oxygen species (ROS) promotion, oxidative stress and inflammation in runners (n = 46) participating in a 330km UMT from capillary blood sample using micro-invasive analytic methods \[[@pone.0180322.ref007]\]; others evidenced a respiratory muscle strength reduction in inspiratory muscles when running a 110km UMT (n = 22) \[[@pone.0180322.ref008]\] or even, the adversely impact in the cognitive performance after a 168km UMT race (n = 17) \[[@pone.0180322.ref009]\].

To the best of our knowledge, there are no studies that approach UMT runners' genome-wide gene expression (GE) response. This methodology has been used in other type of exercise-related interventions such as a single bout of 4-hour stationary cycling (n = 5) \[[@pone.0180322.ref010]\] or after a specific running endurance training (n = 13) \[[@pone.0180322.ref011]\]. On the other hand, GE on particular sets of genes has been assessed in shorter distances as marathon races when studying the response of specific interleukins (n = 16) \[[@pone.0180322.ref012]\] or in toll-like receptors (n = 47) \[[@pone.0180322.ref013]\].

A better understanding of the immune and inflammatory response has been the main motivation with regard to peripheral blood sample experiments. The link between exercise and immune system has long been studied tracing the beginning back to 1893 when an exercise-induced leukocytosis was described \[[@pone.0180322.ref014]\]. Prior studies suggest that moderate exercise negatively correlates with upper respiratory tract infections (URTI) incidence among other positive clinical implications \[[@pone.0180322.ref015]\]. However, this may not be the case in marathon or similar events where the opposite effect is detected \[[@pone.0180322.ref016]\]. A mechanistic explanation of an increased URTI risk in marathon runners (n = 16) is proposed elsewhere \[[@pone.0180322.ref017]\]. This study is based on the ratio imbalance of GE values from genes related to T-helper 1 (Th1) and Th2 cells. Likewise, other authors summarized the exercise impact on the GE of common inflammatory markers in a diverse range of exercise disciplines, intensity and duration \[[@pone.0180322.ref018]\].

In other experiments, the use of skeletal muscle biopsy samples is driven by the understanding of the adaptation of the human skeletal muscle to exercise \[[@pone.0180322.ref019]\]. In this context, the role of the hypoxia-inducible factor family (HIF), as reviewed in \[[@pone.0180322.ref020]\], is of great interest since its target genes include the vascular endothelial growth factor (VEGF), which related signalling pathway is one of the events driving the vascular system remodelling known to occur with dynamic exercise \[[@pone.0180322.ref002]\].

In this study, we obtained the genome-wide GE profiling in a group of runners (n = 16) participating in an 82km UMT race. We report the biological pathways and transcriptional regulators enriched by the list of differentially expressed genes as a result of the UMT intervention. For doing so, we addressed the genetic response from a global perspective and from an independent activity approach after implementing a statistical method capable of extracting independent sources of information.

Materials and methods {#sec002}
=====================

Ethical approval {#sec003}
----------------

All procedures involved in this study conformed to the Declaration of Helsinki. Ethical approval was granted by the Ethics Committee of the Catalan Sports Council from Government of Catalonia (Approval number 0099S/2046/2013). Written informed consent was obtained from all individuals participating in the study.

Experimental design {#sec004}
-------------------

We approached and recruited 18 healthy runners who accepted to voluntarily participate in the study. They were athletes with prior experience in UMTs and presented no muscle injuries in the previous six months. One of the subjects dropout so finally, a total of 17 runners participated in the study (12 males aged 38.2 ± 4.3 years, 5 females aged 35.6 ± 2.2 years). All individuals were of Western European descent. [Table 1](#pone.0180322.t001){ref-type="table"} shows basic anthropometrical measures and weekly training hours per participant. The experiment was conducted in June 2012 at the "Cavalls del Vent" UMT located in the Catalan Pyrenees (Spain). This was a circular 82 km route starting at 760m above sea level and achieving a maximum altitude of 2,520m. The total accumulated altitude change was 12,180 m. In previous edition (2011), male and female winners needed 8.9 hours and 11.6 hours respectively to complete the race while last finishers took approximately 22 hours (no gender differentiation) to cover the total distance.

10.1371/journal.pone.0180322.t001

###### Participants in the study--age, basic anthropometric and training regime.

![](pone.0180322.t001){#pone.0180322.t001g}

  Participant id   Gender   Age \[years\]   Height \[cm\]   Weight \[kg\]   Training regime \[hours per week\]
  ---------------- -------- --------------- --------------- --------------- ------------------------------------
  1                Female   35.9            167             58.0            \-
  2                Female   38.4            164             60.0            15
  3                Male     45              171             72.0            6
  4                Male     41.8            172             70.0            7.5
  5                Male     37.1            184             74.2            5.5
  6                Male     40.3            164             55.0            15
  7                Male     36.8            183             75.6            10
  8                Female   39.1            173             67.0            15
  9                Male     37.1            176             68.0            \-
  10               Male     41.5            182             91.4            5
  11               Male     38.1            178             78.0            7
  12               Male     40.3            179             71.0            5
  13               Male     27.6            167             59.2            7.5
  14               Male     35.8            180             84.0            5
  15               Female   41.9            \-              \-              \-
  16               Male     37              165             53.7            \-
  17               Female   37.6            \-              \-              5

Blood samples, RNA extraction and microarray expression data {#sec005}
------------------------------------------------------------

Venous blood samples were drawn, at rest in a sitting position, from the antecubital vein and collected into PAXgene Blood RNA Tubes according to the manufacturer's protocol (PreAnalytiX GmbH/QIAGEN, Switzerland/US). Samples were obtained from each subject prior to and immediately after the UMT, with the exception of five participants (ids 1, 9, 13, 15 and 16 as shown in [Table 2](#pone.0180322.t002){ref-type="table"}) from whom only pre-race samples were available. A total of 29 samples, 17 of them corresponding to pre-race and 12 to post-race, were stored at -80°C until assayed in the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain). Samples were tagged with an identifier followed by PRE or POST referring to pre- or post-race sample. Total RNA was isolated using the PAXgene Blood RNA kit (PreAnalytiX GmbH/QIAGEN, Switzerland/US). The concentration of the extracted RNA was measured spectrophotometrically (Nanodrop 1000/ Thermo Fisher Scientific, Wilmington, US). GeneChip WT Plus Reagent kit (Affymetrix Inc., California US) was used for processing 100ng of total RNA per sample. Biotinylated sscDNA was hybridized for 16 hour at 45°C and 60 rpm on HuGene2.0st microarrays in a Hybridization Oven 640, both from Affymetrix. Microarrays were washed and stained in the Affymetrix Fluidics Station 450. Finally, they were confocal scanned using the GeneChip 3000 7G with Autoloader from Affymetrix. Raw fluorescence intensity values were stored in Chip Expression Level (CEL) file types, one per available blood sample. Data is available in the Gene Expression Omnibus database (GSE93945).

10.1371/journal.pone.0180322.t002

###### Completed distance, time achieved and average speed per study participant.

Table indicates the race performance for each participant in the study. Biological sample availability is indicated in terms of pre- or post- race extraction.
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  Participant                                 Sample availability   Completed distance \[km\]   Time achieved \[hours\]   Average speed \[km/h\]
  ------------------------------------------- --------------------- --------------------------- ------------------------- ------------------------
  1                                           Pre-race              82                          10.6                      7.7
  2                                           Pre- and Post-race    82                          11.5                      7.1
  3                                           Pre- and Post-race    50                          10.0                      5
  4                                           Pre- and Post-race    50                          10.0                      5
  5                                           Pre- and Post-race    25                          7.0                       3.6
  6                                           Pre- and Post-race    42                          4.5                       9.3
  7                                           Pre- and Post-race    50                          10.0                      5
  8                                           Pre- and Post-race    82                          11.5                      7.1
  9[^(1)^](#t002fn001){ref-type="table-fn"}   Pre-race              58                          5.3                       10.9
  10                                          Pre- and Post-race    25                          7.0                       3.6
  11                                          Pre- and Post-race    33                          5.0                       6.6
  12                                          Pre- and Post-race    50                          10.0                      5
  13                                          Pre-race              28                          6.1                       4.6
  14                                          Pre- and Post-race    50                          10.0                      5
  15                                          Pre-race              Unknown                     Unknown                   Unknown
  16                                          Pre-race              Unknown                     Unknown                   Unknown
  17                                          Pre- and Post-race    14                          3.1                       4.5

^(1)^This sample was removed for downstream analysis due to negative Quality Control results.

The corresponding expression profiles from the CEL files were background corrected, quantile normalized and summarized using the Robust Multichip Average (RMA) \[[@pone.0180322.ref021]\] on the R software platform \[[@pone.0180322.ref022]\] with BioConductor \[[@pone.0180322.ref023]\] using the oligo package \[[@pone.0180322.ref024]\]. The expression levels of 53,617 transcript clusters (TCs) were available per sample. Quality control (QC) was performed over pre-processed data to detect possible outliers based on the following metrics: relative log expression \[[@pone.0180322.ref025]\], normalized unscaled standard error \[[@pone.0180322.ref025]\], density intensity distributions (histogram and boxplot) and principal component analysis (PCA). Relevant versions of used packages are given in [S1 Table](#pone.0180322.s007){ref-type="supplementary-material"}.

Differential gene expression analysis (DGEA) {#sec006}
--------------------------------------------

Only those TCs targeting protein-coding RNA molecules were considered for DGEA based on the annotation from the *hugene20sttranscriptcluster*.*db* package \[[@pone.0180322.ref026]\]. A non-supervised filtering \[[@pone.0180322.ref027]\] was applied to discard low expressed TCs which were assumed to be non-informative. TCs with expression values higher than the overall intensity mean, computed across all arrays, and on more than 12 arrays were selected for DGEA. The genefilter package \[[@pone.0180322.ref028]\] was used for this purpose. Then, a linear regression model (LM) was fitted to each TC expression value according to Eq ([1](#pone.0180322.e001){ref-type="disp-formula"}). $$g_{k} = \beta_{0k} + \beta_{1k} \bullet g + \beta_{2k} \bullet d + \epsilon_{k}$$ where *g*~*k*~ is the expression value of TC *k*, *β*~0*k*~ is the LM intercept for TC expression value *k*, *β*~1*k*~ and *β*~2*k*~ are the unknown coefficients for the variables gender *g* and distance *d* respectively and *ϵ*~*k*~ are the random errors. The empirical Bayes moderated t-statistics tested whether each individual coefficient was zero using the *limma* package \[[@pone.0180322.ref029]\]. Statistically significant differentially expressed TCs (differential TCs) were selected and ranked (adjusted p-value \< 5%, FDR) per LM predictor variable. Entrez Gene identifiers (IDs) were mapped from their differential TCs.

The resulting list of differential genes was used as input for the downstream analysis ([Fig 1](#pone.0180322.g001){ref-type="fig"}). A heatmap was generated with *gplots* package \[[@pone.0180322.ref030]\] for selected TCs including a hierarchical clustering with complete linkage method.

![Complete workflow implemented for the study.\
The differential genes list obtained from the differential gene expression analysis is taken as the initial step for the workflow. This represents the global response to intervention but can also be decomposed in independent components through an Independent Component Analysis (ICA) to obtain the independent block response. ICA is computed after applying a deflation method to the original expression data. Gene and transcriptional regulator (TR) enrichment analyses are computed over the global and independent response. Results are summarized in overrepresented pathway graphs and overrepresented TRs rankings.](pone.0180322.g001){#pone.0180322.g001}

Independent activity analysis {#sec007}
-----------------------------

Microarray expression data could be understood as a linear combination of independent expression sources, each one associated with a particular biological reading \[[@pone.0180322.ref031]\]. We computed an Independent Component Analysis (ICA) to extract these expression sources \[[@pone.0180322.ref032]\] according to Eq ([2](#pone.0180322.e002){ref-type="disp-formula"}). $$\mathbf{X}^{\mathbf{T}} = \mathbf{S}\mathbf{A}$$ where **X** is an *n* × *m* matrix of the expression values of *n* genes under *m* array samples. The columns of the *m* × *k* source matrix **S** contain *k* independent components (ICs) and the *k* × *n* matrix **A** represents the linear mixing matrix. The row of matrix **A** comprises the weights with which the expression levels of the *n* genes contribute to each *k*^*th*^ expression mode.

The list of differential genes was selected to build a matrix **X**. First, the optimum number of *k* ICs for **X** was obtained by estimating the optimal number of components in the PCA using the generalized cross-validation approximation (GCV) and the smoothing method \[[@pone.0180322.ref033]\], both implemented in the *FactoMineR* package \[[@pone.0180322.ref034]\]. Then a deflationary method was applied to **X** to remove the first component of variance as computed by the PCA. This was applied to eliminate the main response to the intervention characterized by the immune system and the genetic information processes as latter shown. These powerful signals act as a masking effect for the rest of underlying processes making difficult for ICA to detect them. Deflation was applied according to Eq ([3](#pone.0180322.e003){ref-type="disp-formula"}): $$\mathbf{Y}^{\mathbf{T}} = \mathbf{z}_{\mathbf{i}1} \otimes \mathbf{\phi}_{\mathbf{j}1}$$ where **Y** is an *n* × *m* matrix which refers to the expression values of *n* genes from *m* array samples captured by the first principal component (PC1), **z**~**i1**~ is the scores vector of the *i*~*th*~ array sample in PC1 and **ϕ**~**j1**~ corresponds to the loadings vector of the *j*~*th*~ gene. Lastly, an estimated matrix ${\hat{\mathbf{X}}}^{\mathbf{T}}$ was built according to Eq ([4](#pone.0180322.e005){ref-type="disp-formula"}): $${\hat{\mathbf{X}}}^{\mathbf{T}} = \mathbf{X}^{\mathbf{T}} - \mathbf{Y}^{\mathbf{T}}$$

ICA was performed over both the matrixes **X**^**T**^ and ${\hat{\mathbf{X}}}^{\mathbf{T}}$ where *k* − 1 ICs were considered in the second case due to the applied deflation. The *fastICA* package was used \[[@pone.0180322.ref035]\] (ε~t~ \<1e-4, *G* ≈ *log cosh* with *α*~1~ = 1 \[[@pone.0180322.ref032]\], ICs extracted simultaneously). Those genes with absolute weight value included in the ninth decile were considered as the most representative genes for each specific IC.

Gene enrichment analysis (GEA) {#sec008}
------------------------------

A GEA was applied in two stages: (i) globally when considering the list of differential genes and (ii) specifically for each IC derived from ICA and only considering the most representative genes. GEA was computed over Kyoto Encyclopedia of Genes and Genoms (KEGG) PATHWAY \[[@pone.0180322.ref036]\], Reactome \[[@pone.0180322.ref037]\] and The Gene Ontology (GO) Biological Processes \[[@pone.0180322.ref038]\] databases with the package *clusterProfiler* \[[@pone.0180322.ref039]\]. For each queried biological pathway or GO term, an adjusted p-value was calculated with a hypergeometric distribution test (adjusted p-value \< 5%, False Discovery Rate FDR). The background distribution was defined by all available annotations in the relevant database or by the list of differential genes if the global or ICA stage was considered, respectively.

Transcriptional regulator enrichment analysis (TREA) {#sec009}
----------------------------------------------------

To explore overrepresented transcriptional regulators (TRs) as a response to UMT completed distance, a TREA was conducted. We considered differential genes to be potentially regulated by one or more TRs. The TREA was implemented with a hypergeometric model to assess whether the number of differential genes related to a specific TR was larger than expected. TRs were ranked based on their adjusted p-values (\<5%, FDR). The TREA was implemented in two stages, globally and specifically per IC. A compilation of interactions between human TRs and target genes (TGs) was obtained from the Open Regulatory Annotation (ORA) database v3.0 \[[@pone.0180322.ref040]\]. Interactions between 196 regulatory elements and 23,991 TGs were chosen (*type* of regulation was set to *transcription factor binding site*, GRCh37/hg19). Background distribution was defined by the complete customized database or by the list of differential genes if the global or ICA stage was considered, respectively.

Results {#sec010}
=======

Only 3 out of the 17 initial participants in the study finished the UMT while the rest of volunteers decided to leave the race at different distances along the trail. This was due to the adverse weather conditions mainly because of low temperatures (from 0.9°C to 13.1°C) and rain presence (from 0 to 6.1mm/h). The corresponding completed distance per participant and respective achieved time is given in [Table 2](#pone.0180322.t002){ref-type="table"}. Additionally, biological sample availability is commented relative to its extraction before and/or after the race (pre- and post-race respectively).

QC excluded one pre-race sample, without post-race counterpart, which showed an abnormal pattern ([S1 Fig](#pone.0180322.s001){ref-type="supplementary-material"}). Pre-processing and QC was repeated after its removal with positive results. Therefore, a total of 28 samples, 16 of them pre-race and 12 post-race, were kept for further analysis. After filtering by target protein-coding RNA molecules, 25,272 TCs were available for DGEA. This group of TCs interrogated 22,072 different genes. To visualize their main source of variance, a PCA was conducted over their expression values. PC1 captured 25% of the total data variance, this being aligned with the effect of participating in the UMT ([Fig 2](#pone.0180322.g002){ref-type="fig"}).

![Principal component analysis (PCA) over the expression values of the ranked transcript clusters (TCs).\
(a) PCA over 25,272 TCs expression values targeting protein coding RNA molecules included in HuGene20st microarray. First principal component was aligned with the effect of participating in the Ultra Marathon Trail (UMT) (b) Proportion (in %) of captured variance per principal component.](pone.0180322.g002){#pone.0180322.g002}

DGEA reveals a list of 5084 distinct genes responding to intervention {#sec011}
---------------------------------------------------------------------

DGEA identified 5,974 differential TCs as a response to UMT (β~2~ ≠ 0). Among the list of 5,974 differential TCs, 5,499 were unambiguously annotated to a single gene ([S2 Table](#pone.0180322.s008){ref-type="supplementary-material"}) while 475 had multiple annotations ([S3 Table](#pone.0180322.s009){ref-type="supplementary-material"}). The list of 5,499 differential TCs corresponded to 5,084 distinct genes which were mainly down-regulated (63%) rather than up-regulated (37%). No TC appeared with statistical correlation with runners' age. [Fig 3](#pone.0180322.g003){ref-type="fig"} shows an unsupervised clustering analysis of a subset from the latter 5,499 differential TCs. The figure indicates a coherent sorting of samples prior to UMT compared to posterior ones, except for one misclassified sample labelled as *17_POST* which corresponds to an individual who only completed 17% of the UMT. DGEA additionally revealed 35 differential TCs ([S4 Table](#pone.0180322.s010){ref-type="supplementary-material"}) related to gender (β~1~ ≠ 0, all TCs with single gene annotation). A 43% of these differential genes showed a higher expression level in male than in female runners.

![Heatmap of the ranked transcript clusters (TCs) with stronger effect as response to the intervention.\
Heatmap of the TCs with stronger effect as response to completed distance in the Ultra Marathon Trail (UMT). Selection was based on β~2~ values obtained in the linear model. Those TCs with *abs*(β~2~) \> $\mu_{\beta_{2}} + {2\sigma}_{\beta_{2}}$ were chosen corresponding to 1,115 among the 5,499 differential TCs.](pone.0180322.g003){#pone.0180322.g003}

Global response {#sec012}
---------------

### Pathways associated with genetic information processing, infectious diseases and immune system are mainly affected {#sec013}

The 5,804 differential genes were used to conduct a global GEA for each of the three databases: KEGG, Reactome and GO Biological Processes. Results obtained from KEGG revealed a list of 42 statistically overrepresented pathways ([Table 3](#pone.0180322.t003){ref-type="table"}). All of them were connected through 978 out of the 5,084 initial differential genes ([Fig 4](#pone.0180322.g004){ref-type="fig"}). According to the database structure, 11 among the 42 induced pathways were involved in genetic information processing with most of their annotated genes down-regulated (mean 86.7% ± standard deviation 11.1%). A total of 11 affected infectious diseases were distributed among bacterial (three), viral (five) and parasitic (three) infection types. Genes annotated to bacterial and parasitic pathways were up-regulated by 61.5% ± 3.6% and 61.2% ± 8%, respectively. Genes annotated to the viral pathways were mostly down-regulated by 59.7% ± 5.3%. Nine pathways from the immune system emerged, including specific signalling pathways (three) and related immune diseases (two). No significant common sense of regulation was observed in this case with the exception of the two immune diseases, both mainly down-regulated (62.1% and 88.9%). Both lymphoid and myeloid cell lines from the *hematopoietic cell lineage* pathway were impacted ([S2 Fig](#pone.0180322.s002){ref-type="supplementary-material"}). Cell surface molecules included in this pathway (26 out of 55) were showing up-regulation (CD1, CD11b, CD13, CD14, CD35, CD36, CD42, CD55, CD59, CD114, CD116, CD121, CD124 and CD126) or down-regulation (CD2, CD3, CD5, CD7, CD8, CD20, CD24, CD38, CD49, CD71, CD125 and CD127). Other overrepresented pathways refer to signal transduction such as signalling pathways for HIF-1 and Nuclear Factor NF-κβ, with 58.1% and 53.8% of the annotated genes up-regulated respectively. Several cellular processes, as *apoptosis* (with 52.6% of annotated genes up-regulated) and *cell cycle* (with 79.6% of annotated genes down-regulated) were also impacted. The complete list of up-and down-regulated genes per listed pathway is enclosed in [S5 Table](#pone.0180322.s011){ref-type="supplementary-material"}.

![Network of the overrepresented Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways listed in [Table 3](#pone.0180322.t003){ref-type="table"} connected through their differential annotated genes.\
Statistically significant overrepresented KEGG pathways within the 5,084 distinct genes with marked differential expression level as a response to endurance exercise. Pathway's circle size is proportional to the number of annotated genes (node degree). Pathway's node color refers to their specific main category according to the KEGG structure. Genes annotated to each pathway are color-coded according to their type of regulation (green codes for down-regulation and red for up-regulation).](pone.0180322.g004){#pone.0180322.g004}

10.1371/journal.pone.0180322.t003

###### List of the 42 overrepresented Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways as a response to the intervention.

*KEGG pathway identifier (ID)* and *description* is enclosed in the table. Pathway's *main category* and *subcategory* are shown. *Gene*:*Bg Ratio* indicates the number of genes annotated to a pathway (within the specific list of 1,905 out of 5,084 differential genes which appear in KEGG database) versus the number of genes annotated to that specific pathway within the background. Background considers all genes included in the database which corresponds to 6,997 elements. Pathways are sorted based on their *adj p-val* (FDR correction) coded as \*\*\* \< 0.001, \*\* \< 0.01 and \* \< 0.05. *Up-reg\[%\]* indicates the percentage of differential genes annotated to the specific pathway being up-regulated.

![](pone.0180322.t003){#pone.0180322.t003g}

  ---------------------------------------------------------------------------------------------------------------------------------
  KEGG Pathway ID:Description                           Main Category---Subcategory              Gene:\     adj\     Up-reg \[%\]
                                                                                                 Bg Ratio   p-val    
  ----------------------------------------------------- ---------------------------------------- ---------- -------- --------------
  hsa03010:Ribosome                                     GIP---Translation                        75:137     \*\*\*   4

  hsa04141:Protein processing in ER                     GIP---Folding, sorting and degradation   80:169     \*\*\*   26.2

  hsa04660:T cell receptor SP                           OS---Immune system                       52:104     \*\*\*   32.7

  hsa03040:Spliceosome                                  GIP---Transcription                      61:134     \*\*\*   14.8

  hsa05152:Tuberculosis                                 HD---Infectious Diseases: Bacterial      76:178     \*\*\*   60.5

  hsa04380:Osteoclast differentiation                   OS---Development                         59:131     \*\*\*   72.9

  hsa04621:NOD-like receptor SP                         OS---Immune system                       30:57      \*\*     63.3

  hsa04120:Ubiquitin mediated proteolysis               GIP---Folding, sorting and degradation   59:137     \*\*     22

  hsa04142:Lysosome                                     CP---Transport and catabolism            54:123     \*\*     64.8

  hsa05134:Legionellosis                                HD---Infectious Diseases: Bacterial      29:55      \*\*     65.5

  hsa05169:Epstein-Barr virus infection                 HD---Infectious Diseases: Viral          80:202     \*\*     40

  hsa05145:Toxoplasmosis                                HD---Infectious Diseases: Parasitic      51:118     \*\*     52.9

  hsa03430:Mismatch repair                              GIP---Replication and repair             15:23      \*\*     0

  hsa04722:Neurotrophin SP                              OS---Nervous system                      51:120     \*\*     60.8

  hsa05168:Herpes simplex infection                     HD---Infectious Diseases: Viral          72:185     \*\*     36.1

  hsa04210:Apoptosis                                    CP---Cell growth and death               38:85      \*\*     52.6

  hsa03013:RNA transport                                GIP---Translation                        67:172     \*\*     14.9

  hsa04066:HIF-1 SP                                     EIP---Signal transduction                43:103     \*       58.1

  hsa04910:Insulin SP                                   OS---Endocrine system                    55:139     \*       56.4

  hsa05166:HTLV-I infection                             HD---Infectious Diseases: Viral          93:258     \*       36.6

  hsa03018:RNA degradation                              GIP---Folding, sorting and degradation   34:77      \*       11.8

  hsa03050:Proteasome                                   GIP---Folding, sorting and degradation   22:44      \*       9.1

  hsa03008:Ribosome biogenesis in eukaryotes            GIP---Translation                        38:89      \*       7.9

  hsa04064:NF-kappa B SP                                EIP---Signal transduction                39:93      \*       53.8

  hsa05140:Leishmaniasis                                HD---Infectious Diseases: Parasitic      32:73      \*       68.8

  hsa00280:Valine, leucine and isoleucine degradation   M---Amino acid metabolism                23:48      \*       21.7

  hsa05162:Measles                                      HD---Infectious Diseases: Viral          53:136     \*       39.6

  hsa04110:Cell cycle                                   CP---Cell growth and death               49:124     \*       20.4

  hsa05131:Shigellosis                                  HD---Infectious Diseases: Bacterial      29:65      \*       58.6

  hsa05321:Inflammatory bowel disease (IBD)             HD---Immune diseases                     29:65      \*       37.9

  hsa04612:Antigen processing and presentation          OS---Immune System                       33:77      \*       12.1

  hsa05142:Chagas disease                               HD---Infectious Diseases: Parasitic      42:104     \*       61.9

  hsa04650:Natural killer cell mediated cytotoxicity    OS---Immune System                       52:135     \*       36.5

  hsa04666:Fc gamma R-mediated phagocytosis             OS---Immune System                       38:93      \*       63.2

  hsa03030:DNA replication                              GIP---Replication and repair             18:36      \*       0

  hsa04640:Hematopoietic cell lineage                   OS---Immune System                       36:88      \*       50

  hsa04130:SNARE interactions in vesicular transport    GIP---Folding, sorting and degradation   17:34      \*       35.3

  hsa05340:Primary immunodeficiency                     HD---Immune diseases                     18:37      \*       11.1

  hsa00510:N-Glycan biosynthesis                        M---Glycan biosynthesis and metabolism   22:49      \*       9.1

  hsa05164:Influenza A                                  HD---Infectious Diseases: Viral          63:175     \*       49.2

  hsa04662:B cell receptor SP                           OS---Immune system                       30:73      \*       56.7

  hsa05203:Viral carcinogenesis                         HD---Cancers: Overview                   72:205     \*       52.8
  ---------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GIP, Genetic Information Processing; OS, Organismal System; HD, Human Diseases; CP, Cellular Processes; EIP, Environmental Information Processing; M, Metabolism; SP, Signaling Pathway.

A total of 193 Reactome pathways were found statistically overrepresented ([S6 Table](#pone.0180322.s012){ref-type="supplementary-material"}). [Table 4](#pone.0180322.t004){ref-type="table"} shows a summary by clustering them into parental superclasses based on the database hierarchy. *Gene Expression*, *Immune System* and *Disease* were top affected superclasses which enclose biological information similar to abovementioned KEGG genetic information processing, immune system and infectious disease. Obtained Reactome pathways related to *Disease* were all concentrated on viral infectious diseases capturing 21 out of the 193 ranked pathways.

10.1371/journal.pone.0180322.t004

###### Clustering of the 193 statistically overrepresented Reactome pathways into parental superclasses.

Table shows the number of overrepresented pathways annotated to each existing parental superclass according to database structure.

![](pone.0180322.t004){#pone.0180322.t004g}

  --------------------------------------------------------------------------------------------------
  Reactome Pathway (Parental superclass)\              Number of Overrepresented pathways obtained
  ID:Description                                       
  ---------------------------------------------------- ---------------------------------------------
  R-HSA-1640170:Cell Cycle                             43

  R-HSA-74160:Gene Expression                          38

  R-HSA-168256:Immune System                           36

  R-HSA-1643685:Disease                                21

  R-HSA-392499:Metabolism of proteins                  20

  R-HSA-69306:DNA Replication                          14

  R-HSA-73894:DNA Repair                               11

  R-HSA-162582:Signal Transduction                     8

  R-HSA-1430728:Metabolism                             5

  R-HSA-5357801:Programmed Cell Death                  4

  R-HSA-1852241:Organelle biogenesis and maintenance   4

  R-HSA-2262752:Cellular responses to stress           4

  R-HSA-4839726:Chromatin organization                 3

  R-HSA-109582:Hemostasis                              2
  --------------------------------------------------------------------------------------------------

A total of 1,232 GO terms from Biological Processes ontology were statistically overrepresented ([S7 Table](#pone.0180322.s013){ref-type="supplementary-material"}). *Translation* GO term was the most overrepresented based on this list ([S3 Fig](#pone.0180322.s003){ref-type="supplementary-material"}).

### Comparison with the literature linked to common inflammatory markers and Th1/Th2 related genes {#sec014}

Regarding the immune system, we compared our results with gene expression studies focused on common inflammatory markers after a single exercise intervention in humans ([Table 5](#pone.0180322.t005){ref-type="table"}) as reviewed by other authors \[[@pone.0180322.ref018]\]. Different intervention types were considered in this review, but none of them referred to an UMT.

10.1371/journal.pone.0180322.t005

###### Differential expressed genes related to common inflammatory markers.

List is based on the review presented by other authors \[[@pone.0180322.ref018]\]. *Gene symbol* and *name* are indicated for each marker in the list. ↓ indicates genes being down-regulated and ↑ genes being up-regulated in *Reg* column. *Prior results* refer to studies where the expression of the specific marker was evaluated in a single exercise-related intervention in humans. Genes are sorted in alphabetical order.

![](pone.0180322.t005){#pone.0180322.t005g}

  Gene Symbol                                                                                                                                                             Gene name                                                                         Reg     Prior results
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------- -------------------------------
  CCL5 [^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                    chemokine (C-C motif) ligand 5                                                    ↓       \[[@pone.0180322.ref041]\]
  CCR2[^(^\*^)^](#t005fn002){ref-type="table-fn"}, CCR4[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                    chemokine (C-C motif) receptor 2 and 4                                            ↑ ↓     \[[@pone.0180322.ref017]\]
  CXCL16[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                   chemokine (C-X-C motif) ligand 16                                                 ↑       \[[@pone.0180322.ref042]\]
  GATA3[^(^\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                        GATA binding protein 3                                                            ↓       \[[@pone.0180322.ref017]\]
  GPX4[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"} and GPX7[^(^\*\*^)^](#t005fn002){ref-type="table-fn"}                                                               glutathione peroxidase 4 and 7                                                    ↓ ↓     \[[@pone.0180322.ref043]\]
  HSPA6[^(^\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                      heat shock 70kDa protein 6 (HSP70B\')                                             ↑       \[[@pone.0180322.ref044]\]
  IFNGR2[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                   interferon gamma receptor 2                                                       ↑       \[[@pone.0180322.ref045]\]
  IL1RN[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"} and IL1R1[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                           interleukin 1 receptor antagonist and type I                                      ↑ ↑     \[[@pone.0180322.ref012]\]
  IL10RB [^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"} and IL10RB-AS1[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                    interleukin 10 receptor beta and antisense RNA 1                                  ↑ ↑     \[[@pone.0180322.ref046]\]^1^
  IL1B[^(^\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                         interleukin 1, beta                                                               ↑       \[[@pone.0180322.ref012]\]
  IL4R[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                     interleukin 4 receptor                                                            ↑       \[[@pone.0180322.ref017]\]^2^
  IL6R[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"} and IL6ST[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                            interleukin 6 receptor and signal transducer                                      ↑ ↓     \[[@pone.0180322.ref047]\]^3^
  MMP9[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                     matrix metallopeptidase 9                                                         ↑       \[[@pone.0180322.ref048]\]
  SOD1[^(^\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                       superoxide dismutase 1, soluble                                                   ↓       \[[@pone.0180322.ref049]\]
  TLR2[^(^\*\*^)^](#t005fn002){ref-type="table-fn"} and TLR4[^(^\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                 toll-like receptor 2 and 4                                                        ↑ ↑     \[[@pone.0180322.ref013]\]
  TGFBR3[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}^,^ TGFBR3L[^(^\*\*^)^](#t005fn002){ref-type="table-fn"} and TGFBRAP1[^(^\*^)^](#t005fn002){ref-type="table-fn"}   transforming growth factor beta receptor III, III-like and associated protein 1   ↓ ↑ ↓   \[[@pone.0180322.ref047]\]
  TNF[^(^\*\*\*^)^](#t005fn002){ref-type="table-fn"}                                                                                                                      tumor necrosis factor                                                             ↑       \[[@pone.0180322.ref050]\]

Results reported on ^1^IL10, ^2^IL4, ^3^IL6.

^(\*\*\*)^, ^(\*\*)^ and ^(\*)^ indicate an adjusted p-value (FDR) \< 0.001, \< 0.01 and \< 0.05 respectively.

We reproduced the same sense of immune imbalance as in \[[@pone.0180322.ref017]\] where the Th1/Th2 ratio was assessed one week after a marathon race. Although there is a partial overlap in the ranked genes ([Table 6](#pone.0180322.t006){ref-type="table"}) with regard to prior study, we also observed a down-regulation trend in Th1 cytokines and related genes. Of note is the up-regulation of CEBPB which was previously related to Th2 cell response enhancer \[[@pone.0180322.ref051]\].

10.1371/journal.pone.0180322.t006

###### Differential expressed genes related to T-helper 1 and T-helper 2 cells from immune system.

Th1 and Th2 cytokines and related genes with differential expression are listed.
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  Th1/Th2       Regulation                                                                                                                                                                                                                                                                                                                                                                                         Gene Symbol
  ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Th1 related   Up                                                                                                                                                                                                                                                                                                                                                                                                 TNF[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, [TLR4]{.ul}[^(^\*\*^)^](#t006fn001){ref-type="table-fn"}
  Down          [STAT1]{.ul}[^(^\*\*^)^](#t006fn001){ref-type="table-fn"}, STAT4[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, [TBX21]{.ul}[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, CD28[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, SOCS1[^(^\*\*^)^](#t006fn001){ref-type="table-fn"}, [SOCS5]{.ul}[^(^\*^)^](#t006fn001){ref-type="table-fn"}                                                     
  Th2 related   Up                                                                                                                                                                                                                                                                                                                                                                                                 IL1R1[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, IL1R2[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, STAT6[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, CEBPB[^(^\*\*^)^](#t006fn001){ref-type="table-fn"}, [CCR2]{.ul}[^(^\*^)^](#t006fn001){ref-type="table-fn"}, [PCGF2]{.ul}[^(^\*^)^](#t006fn001){ref-type="table-fn"}
  Down          [NFATC2]{.ul}[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, CCL5[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, ICOS[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, MAF[^(^\*\*\*^)^](#t006fn001){ref-type="table-fn"}, [CCR4]{.ul}[^(^\*\*^)^](#t006fn001){ref-type="table-fn"}, GFI1[^(^\*\*^)^](#t006fn001){ref-type="table-fn"}, [GATA3]{.ul}[^(^\*^)^](#t006fn001){ref-type="table-fn"}   

^(\*\*\*)^, ^(\*\*)^ and ^(\*)^ indicate an adjusted p-value (FDR) \< 0.001, \< 0.01 and \< 0.05 respectively. [Underlined markers are coincident with]{.ul} \[[@pone.0180322.ref017]\][.]{.ul}

### Identified overrepresented TRs related to hematopoietic cell lineage proliferation, gluconeogenesis and hypoxia situation {#sec015}

A TREA was computed with 4,772 among the 5,084 differential genes which were annotated as TGs to any of the 196 available regulatory elements. [Table 7](#pone.0180322.t007){ref-type="table"} shows the 27 statistically overrepresented TRs. Only 10 among the 27 ranked TRs had been previously prioritized by the DGEA. From the list, RBL2, RB1 \[[@pone.0180322.ref052]\] or CTCF \[[@pone.0180322.ref053]\] are directly involved in chromatin structure modifications. Elements capable of interacting appeared simultaneously. E2F4 binds with high affinity to RBL2 and possibly binds with RB1 which interacts with E2F1 \[[@pone.0180322.ref054]\]. Eight known transcription factor (TF) families emerged significant (E2F, ETS, FOS, STAT, EGR, GATA, HIF and RUNX). Most of them are related to general processes such as cell cycle, cell proliferation and development. RUNX1, GATA2 and GATA3 act in the development and proliferation of the hematopoietic cell lineage where GATA2 has been considered elsewhere as the master regulator of hematopoietic progenitor cells \[[@pone.0180322.ref055]\]. TAL1, which collaborates with GATA1, is implicated in several aspects of the final differentiation of red blood cells \[[@pone.0180322.ref056]\]. HNF4, EGR1, CEBPA and YY1 are TRs described in the gluconeogenesis program in response to a fasting state \[[@pone.0180322.ref057]\]. HIF1A and EPAS1 are members of the HIF family whose respective signalling pathways were overrepresented. YY1 and EPAS1 are the most selective TFs obtained with, respectively, 90 and 265 out of 23,991 annotated TGs.

10.1371/journal.pone.0180322.t007

###### List of the 27 statistically overrepresented transcriptional regulators (TRs) as a response to the intervention.

*TR symbol* and *name* are indicated for each TR in the list. *Gene*:*Bg Ratio* indicates the number of target genes regulated by the TR (within the specific list of 4,772 out of 5,084 differential genes which appear in customized TR database obtained from Open Regulatory Annotation database) versus the number of target genes regulated by the TR within the background. Background considers 23,991 genes included in the customized database for TR Enrichment Analysis (TREA). TRs are sorted based on their *adj p-val* (FDR correction) coded as \*\*\*\<0.001, \*\* \< 0.01 and---in case \> 0.05. Last column indicates the *adj p-val* obtained from Differential Gene Expression Analysis (DGEA).
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  TR Symbol   TR name                                                                                             Gene:Bg Ratio   adj p-val   adj p-val (DGEA)
  ----------- --------------------------------------------------------------------------------------------------- --------------- ----------- ------------------
  E2F4        E2F TF 4, p107/p130-binding                                                                         2356:6348       \*\*\*      \-
  ETS1        ETS proto-oncogene 1, TF                                                                            3453:9824       \*\*\*      \*\*
  RBL2        retinoblastoma-like 2                                                                               3642:11908      \*\*\*      \*\*\*
  SMARCA4     SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4   3859:14198      \*\*\*      \-
  RB1         retinoblastoma 1                                                                                    2548:8017       \*\*\*      \-
  SPI1        Spi-1 proto-oncogene                                                                                1190:2941       \*\*\*      \*\*\*
  TFAP2C      TF AP-2 gamma (activating enhancer binding protein 2 gamma)                                         3187:12776      \*\*\*      \-
  CEBPA       CCAAT/enhancer binding protein (C/EBP), alpha                                                       2904:11477      \*\*\*      \*\*\*
  FOS         FBJ murine osteosarcoma viral oncogene homolog                                                      2474:9444       \*\*\*      \*\*\*
  HNF4A       hepatocyte nuclear factor 4, alpha                                                                  2730:10764      \*\*\*      \-
  STAT1       signal transducer and activator of transcription 1, 91kDa                                           2972:12028      \*\*\*      \*\*
  MITF        microphthalmia-associated TF                                                                        1763:6480       \*\*\*      \-
  CTCF        CCCTC-binding factor (zinc finger protein)                                                          3720:16791      \*\*\*      \-
  EGR1        early growth response 1                                                                             2780:12041      \*\*\*      \*\*
  VDR         vitamin D (1,25- dihydroxyvitamin D3) receptor                                                      423:1238        \*\*\*      \*\*\*
  GATA2       GATA binding protein 2                                                                              1547:6231       \*\*\*      \-
  E2F1        E2F TF 1                                                                                            1453:5846       \*\*\*      \-
  ZNF263      zinc finger protein 263                                                                             856:3144        \*\*\*      \*\*
  FOXP1       forkhead box P1                                                                                     902:3353        \*\*\*      \-
  GATA3       GATA binding protein 3                                                                              1981:8461       \*\*\*      \*\*
  FOXA1       forkhead box A1                                                                                     2685:12055      \*\*\*      \-
  ESR1        estrogen receptor 1                                                                                 1656:7051       \*\*\*      \-
  TAL1        T-cell acute lymphocytic leukemia 1                                                                 864:3489        \*\*\*      \-
  HIF1A       hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix TF)                               204:692         \*\*\*      \-
  RUNX1       runt-related TF 1                                                                                   656:2692        \*\*\*      \-
  EPAS1       endothelial PAS domain protein 1                                                                    73:265          \*\*        \-
  YY1         YY1 TF                                                                                              30:90           \*\*        \-

Abbreviations: TF, transcription factor

Independent response activity {#sec016}
-----------------------------

ICA was computed over a PCA projection at six components determined by the smooth and GCV methods. A matrix with the expression levels of the 5,084 differential genes was used for this purpose. The selection of the number of components was based on the mean error obtained for each number of PCs when applying GCV or smooth method ([S4 Fig](#pone.0180322.s004){ref-type="supplementary-material"}). First PC is capturing a 52% of data variance and threshold corresponding to 80% of cumulative percentage is achieved by six components ([S5 Fig](#pone.0180322.s005){ref-type="supplementary-material"}).

ICA decomposed the input expression matrix of 28 array samples × 5,084 differential genes into the mixing matrix A (6 × 5,084) and source matrix S (28 × 6). The mixing matrix contained the weights of 5,804 differential genes for each six independent response blocks to exercise ([S6 Fig](#pone.0180322.s006){ref-type="supplementary-material"}). A total of 509 main contributors per component were selected corresponding to the highest weight values. [S8 Table](#pone.0180322.s014){ref-type="supplementary-material"} indicates the number of matches between ICs and respective unique representatives which ranged between 22% (IC6) and 44% (IC3).

### Dominance of the immune system {#sec017}

First IC was capturing the induced responses both in the innate and in the adaptive immune system according to GEA results conducted over KEGG and Reactome databases ([S9 Table](#pone.0180322.s015){ref-type="supplementary-material"} and [S10 Table](#pone.0180322.s016){ref-type="supplementary-material"} respectively). A subset of surface cell markers found in global GEA (CD2, CD3, CD7, CD8, CD14, CD36, CD59, CD116 and CD121) plus new CD28 and CD40LG from *hematopoietic cell lineage* was affected. First line of defense for pathogen recognition arisen with toll-like receptors TLR2, TLR4 and TLR5 in different infectious diseases such as *malaria* (adj pval 0.014), *amoebiasis* (adj pval 0.027) and *legionellosis* (adj pval 0.039) according to GEA over KEGG database. They were also present in Reactome overrepresented pathways *MyD88 deficiency* (adj pval 0.041) and *IRAK4 deficiency* (adj pval 0.048). Ribosome pathway from KEGG was enriched from third IC group of genes, aligned with a considerable number of overrepresented Reactome pathways related to translation. Sixth IC was mainly involved with cell cycle and translation process again according to GEA over Reactome. There were not overrepresented pathways in the rest of ICs.

As a result of TREA, 11 regulator elements were found overrepresented from the group of genes from first IC ([S11 Table](#pone.0180322.s017){ref-type="supplementary-material"}). Nine of them were already obtained with the global list of differential genes. GATA2 was found in first and third ICs. ETS1 and SMARCA4, also known as BRG1, were found in fourth IC. There were no overrepresented TRs in the rest of ICs.

### Removal of first line of variance {#sec018}

Previous results provided similar biological insights as the global analysis where all the differential genes were considered. The first line of data variance, accounting for 52% as determined by PC1, featured the immune system response to the intervention. To avoid this, ICA was again computed over the PCA projection at five components after considering the deflationary method over the initial matrix X of 5,084 differential GE levels. Five IC sets were obtained and their 509 main contributors were selected for applying GEA and TREA on each one. The number of matches between them and respective unique elements now ranged between 65% (IC5) and 72% (IC2) ([Table 8](#pone.0180322.t008){ref-type="table"}).

10.1371/journal.pone.0180322.t008

###### Main contributors of the independent components (ICs) after applying deflationary method to differential genes expression matrix.

Main contributors were selected based on their highest weight values after subtracting one-dimensional data approximation (PC1) to differential genes expression matrix. Those located in the ninth decile were chosen, obtaining a total of 509 genes per IC. Table shows the number of matches between components and the elements that were unique per IC.
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  Unique genes   \#IC   IC1   IC2   IC3   IC4   IC5
  -------------- ------ ----- ----- ----- ----- -----
  342            IC1    509   1     1     91    112
  364            IC2          509   142   1     4
  358            IC3                509   4     6
  358            IC4                      509   94
  333            IC5                            509

### Terms relative to electron transport chain, a complex signal transduction network and nervous system {#sec019}

According to GEA results over KEGG ([Table 9](#pone.0180322.t009){ref-type="table"}), first IC elucidated four down-regulated genes responsible for encoding major histocompatibility complex (MHC) class II proteins (HLA-DPA1, HLA-DPB1, HLA-DMA and HLA-DRA) ([Fig 5A](#pone.0180322.g005){ref-type="fig"}). These, together with the up-regulated TNF gene, matched in seven out of the nine overrepresented KEGG pathways, related to immune, autoimmune or alloimmune responses. The second IC presented three neurodegenerative diseases: *Parkinson's*, *Alzheimer's* and *Huntington's diseases* ([Fig 5B](#pone.0180322.g005){ref-type="fig"}). All of them shared 10 down-regulated genes from the electron transport chain (ETC) in the mitochondrion ([Table 10](#pone.0180322.t010){ref-type="table"}). Genes involved in signal transduction stood out among the 24 KEGG pathways enriched from third IC ([Fig 5D](#pone.0180322.g005){ref-type="fig"}). There were two main hubs of signal communication. The up-regulated MAPK3, MAPK13, PIK3R5, PIK3CD genes and the down-regulated MAPK8 and MAPK9 genes characterized one hub. Among them, MAPK3, PIK3R5 and PIK3CD were common for 20 out of the 24 pathways. The other hub was featured by the up-regulated PRKACA and ADCY4, related to cAMP second messengers, and GNAI2 gene. Two pathways associated with the nervous system, *retrograde endocannabinoid signalling* and *morphine addiction*, showed up-regulation in most of their annotated differential genes with a 70% and a 85.7% respectively. GABRD gene which encodes for a neurotransmitter GABA receptor was one of these up-regulated genes. OSCAR and AGER genes, both up-regulated, were respectively specific elements for *osteoclast differentiation* and *AGE-RAGE signalling pathway in diabetic complications* pathways. Five infectious diseases were overrepresented, four of them being of viral origin: *HTLV-I infection*, *hepatitis C*, *hepatitis B* and *influenza A*. The up-regulated SERPINB1 gene was annotated to, inter alia, the overrepresented *amoebiasis* KEGG pathway from fourth IC ([Fig 5C](#pone.0180322.g005){ref-type="fig"}). The role of this gene has been previously related to the mitigation of inflammation in pulmonary influenza infections \[[@pone.0180322.ref058]\]. Genes encoding ribosomal proteins, including mitochondrial ribosomal proteins, characterized the fifth IC.

![Network of the overrepresented Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways listed in [Table 9](#pone.0180322.t009){ref-type="table"}.\
Pathways are connected through their differential annotated genes for each Independent Component (IC) after removing first line of variance. (a) IC1 (b) IC2 (c) IC4 and (d) IC3. Pathway's node size is proportional to the number of annotated genes (node degree). Genes annotated to each pathway are color-coded according to their type of regulation (green codes for down-regulation and red for up-regulation) together with its official gene symbol. SP stands for signalling pathway.](pone.0180322.g005){#pone.0180322.g005}

10.1371/journal.pone.0180322.t009

###### List of the statistically overrepresented Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways obtained for each independent component (IC) after removing first line of variance.

*KEGG pathway ID* and *description* is enclosed in the table. Pathway's *main category* and *subcategory* are shown. *Gene*:*Bg Ratio* indicates the number of genes annotated to a pathway within the specific list of differential genes among the 509 major contributors that are included in the database (i.e. 201 for IC1) versus the number of genes annotated to a pathway within the background. Background considers all differential genes included in KEGG database which corresponds to 1905 elements among 5084 differential genes. Pathways are sorted based on their *adj p-val* (FDR correction) coded as \*\*\* \< 0.001, \*\* \< 0.01 and \* \< 0.05. *Up-reg* indicates the percentage of differential genes annotated to the specific pathway being up-regulated.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#IC                                                                KEGG Pathway ID:Description                     Main Category---Subcategory           Gene:\      adj\     Up-reg \[%\]
                                                                                                                                                            Bg Ratio    p-val    
  ------------------------------------------------------------------- ----------------------------------------------- ------------------------------------- ----------- -------- --------------
  IC1                                                                 hsa05332:Graft-versus-host disease              HD---Immune diseases                  8/201:17    \*       12.5

  hsa05323:Rheumatoid arthritis                                       HD---Immune diseases                            10/201:26                             \*          50       

  hsa05321:Inflammatory bowel disease (IBD)                           HD---Immune diseases                            10/201:29                             \*          30       

  hsa04640:Hematopoietic cell lineage                                 OS---Immune system                              11/201:36                             \*          27.3     

  hsa05330:Allograft rejection                                        HD---Immune diseases                            6/201:13                              \*          16.7     

  hsa04612:Antigen processing and presentation                        OS---Immune system                              10/201:33                             \*          20       

  hsa04940:Type I diabetes mellitus                                   HD---Endocrine and metabolic diseases           6/201:14                              \*          16.7     

  hsa05310:Asthma                                                     HD---Immune diseases                            5/201:10                              \*          20       

  hsa04650:Natural killer cell mediated cytotoxicity                  OS---Immune system                              13/201:52                             \*          23.1     

  IC2                                                                 hsa05012:Parkinson\'s disease                   HD---Neurodegenerative diseases       16/188:46   \*\*\*   0

  hsa03010:Ribosome                                                   GIP---Translation                               20/188:75                             \*\*        0        

  hsa05010:Alzheimer\'s disease                                       HD---Neurodegenerative diseases                 14/188:57                             \*          14.3     

  hsa05016:Huntington\'s disease                                      HD---Neurodegenerative diseases                 14/188:57                             \*          0        

  IC3                                                                 hsa04723:Retrograde endocannabinoid signaling   OS---Nervous system                   10/204:25   \*       70

  hsa04914:Progesterone-mediated oocyte maturation                    OS---Endocrine system                           11/204:30                             \*          63.6     

  hsa05133:Pertussis                                                  HD---Infectious diseases: Bacterial             10/204:28                             \*          70       

  hsa04923:Regulation of lipolysis in adipocytes                      OS---Endocrine system                           7/204:16                              \*          85.7     

  hsa04380:Osteoclast differentiation                                 OS---Development                                15/204:59                             \*          66.7     

  hsa04015:Rap1 signaling pathway                                     EIP---Signal transduction                       14/204:55                             \*          85.7     

  hsa05166:HTLV-I infection                                           HD---Infectious diseases: Viral                 20/204:93                             \*          60       

  hsa05160:Hepatitis C                                                HD---Infectious diseases: Viral                 11/204:38                             \*          54.5     

  hsa04072:Phospholipase D signaling pathway                          EIP---Signal transduction                       12/204:44                             \*          83.3     

  hsa05032:Morphine addiction                                         HD---Substance dependence                       7/204:18                              \*          85.7     

  hsa04724:Glutamatergic synapse                                      OS---Nervous system                             8/204:24                              \*          87.5     

  hsa04917:Prolactin signaling pathway                                OS---Endocrine system                           8/204:24                              \*          62.5     

  hsa04022:cGMP-PKG signaling pathway                                 EIP---Signal transduction                       11/204:41                             \*          63.6     

  hsa04370:VEGF signaling pathway                                     EIP---Signal transduction                       7/204:20                              \*          85.7     

  hsa04930:Type II diabetes mellitus                                  HD---Endocrine and metabolic diseases           7/204:20                              \*          71.4     

  hsa05205:Proteoglycans in cancer                                    HD---Cancers: Overview                          14/204:61                             \*          78.6     

  hsa04510:Focal adhesion                                             CP---Cellular community                         12/204:49                             \*          66.7     

  hsa05212:Pancreatic cancer                                          HD---Cancers: Specific Types                    8/204:26                              \*          37.5     

  hsa04062:Chemokine signaling pathway                                OS---Immune system                              13/204:56                             \*          92.3     

  hsa04550:Signaling pathways regulating pluripotency of stem cells   CP---Cellular community                         9/204:32                              \*          77.8     

  hsa04933:AGE-RAGE signaling pathway in diabetic complications       HD---Endocrine and metabolic diseases           9/204:32                              \*          55.6     

  hsa05161:Hepatitis B                                                HD---Infectious diseases: Viral                 12/204:50                             \*          50       

  hsa04261:Adrenergic signaling in cardiomyocytes                     OS---Circulatory system                         10/204:38                             \*          80       

  hsa05164:Influenza A                                                HD---Infectious diseases: Viral                 14/204:63                             \*          57.1     

  IC4                                                                 hsa05146:Amoebiasis                             HD---Infectious diseases: Parasitic   11/204:27   \*\*     72.7

  hsa04640:Hematopoietic cell lineage                                 OS---Immune system                              12/204:36                             \*          58.3     

  IC5                                                                 hsa03010:Ribosome                               GIP---Translation                     18/176:75   \*       0
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: GIP, Genetic Information Processing; OS, Organismal System; HD, Human Diseases; CP, Cellular Processes; EIP, Environmental Information Processing.

10.1371/journal.pone.0180322.t010

###### Down-regulated genes from the electron transport chain as a response to the intervention.
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  Gene Symbol                                              Gene name                                                                                  ETC Complex
  -------------------------------------------------------- ------------------------------------------------------------------------------------------ -------------
  NDUFA9[^(^\*\*\*^)^](#t010fn001){ref-type="table-fn"}    NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa                               I
  NDUFAB1[^(^\*\*\*^)^](#t010fn001){ref-type="table-fn"}   NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8kDa                          I
  NDUFS6[^(^\*\*^)^](#t010fn001){ref-type="table-fn"}      NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa (NADH-coenzyme Q reductase)          I
  NDUFB4[^(^\*^)^](#t010fn001){ref-type="table-fn"}        NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa                                I
  CYC1[^(^\*\*^)^](#t010fn001){ref-type="table-fn"}        cytochrome c-1                                                                             III
  UQCRQ[^(^\*\*^)^](#t010fn001){ref-type="table-fn"}       ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa                          III
  ATP5A1[^(^\*\*\*^)^](#t010fn001){ref-type="table-fn"}    ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle   V
  ATP5G1[^(^\*\*\*^)^](#t010fn001){ref-type="table-fn"}    ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9)            V
  ATP5J [^(^\*\*^)^](#t010fn001){ref-type="table-fn"}      ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6                        V
  ATP5F1[^(^\*\*^)^](#t010fn001){ref-type="table-fn"}      ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1                        V

^(\*\*\*)^, ^(\*\*)^ and ^(\*)^ indicate an adjusted p-value (FDR) \< 0.001, \< 0.01 and \< 0.05 respectively. ETC, electron transport chain.

A summary of the GEA results over Reactome is included in [S12 Table](#pone.0180322.s018){ref-type="supplementary-material"}. Overrepresented pathways were only found for second and fifth ICs. In line with KEGG results, ETC was also shown in 2 among the 31 enriched pathways in the second IC: *the citric acid (TCA) cycle and respiratory electron transport* and the *respiratory electron transport*, *ATP synthesis by chemiosmotic coupling*, *and heat production by uncoupling proteins* pathways.

### Overrepresented TRs among ICs are aligned with pathway enrichment results {#sec020}

A list of 19 TRs was found overrepresented in IC2, IC3 and IC4 as a result of TREA ([Table 11](#pone.0180322.t011){ref-type="table"}). Most of them, 17 out of the 19, were already prioritized when considering a global response ([Table 7](#pone.0180322.t007){ref-type="table"}). In this case, ETS1 and E2F4 transcription factors were enriched in the second IC. E2F4 belong to E2F family which is known by its dual role in cell proliferation and its contribution to cell death in response to cell stress \[[@pone.0180322.ref059]\]. The third IC showed five enriched TRs (EGR1, VDR, ZNF263, TFAP2C and CTCF) where, as best we know, the last three have an unspecific TR role. EGR1 was connected to MAPK and vascular endothelial growth factor (VEGF) signalling, both highlighted GEA results for IC3 ([Table 9](#pone.0180322.t009){ref-type="table"}), when studying the relationship between insulin sensitivity and exercise-induced gene expression \[[@pone.0180322.ref060]\]. The VDR gene is known to be connected to bone homeostasis \[[@pone.0180322.ref061]\] which is compatible with the presence of osteoclast differentiation pathway ([Table 7](#pone.0180322.t007){ref-type="table"} --IC3). From fourth IC, TP53 and SOX2 genes were the new hits found.

10.1371/journal.pone.0180322.t011

###### List of the statistically overrepresented transcriptional regulators (TRs) obtained per independent component (IC) after removing first line of variance.

Three ICs (IC2, IC3 and IC4) among the computed five components show enriched TRs. *TR symbol* and *name* are indicated for each TR in the list. *Gene*:*Bg Ratio* indicates the number of target genes (TGs) regulated by the specific TR among the 509 major contributor genes versus the number of TGs regulated by the TR within the background. Only those major contributors that appear in the customized TR database obtained from Open Regulatory Annotation (ORA) database per IC are considered (i.e. for IC2, 489 out of the 509 contributors). Background considers 4,772 genes included in the customized ORA database for TR Enrichment Analysis (TREA) among 5,084 differential genes. TRs are sorted based on their *adj p-val* (FDR correction) coded as \*\*\* \< 0.001, \*\* \< 0.01, \* \< 0.05 and---in case \> 0.05. Last column indicates the *adj p-val* obtained from Differential Gene Expression Analysis (DGEA).

![](pone.0180322.t011){#pone.0180322.t011g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#IC      TR symbol                                                                                           TR name                    Gene:Bg Ratio   adj\     adj p-val (DGEA)
                                                                                                                                                           p-val    
  --------- --------------------------------------------------------------------------------------------------- -------------------------- --------------- -------- ------------------
  IC2       ETS1                                                                                                ETS proto-oncogene 1, TF   391/489:3453    \*\*     \*\*\*

  E2F4      E2F TF 4, p107/p130-binding                                                                         275/489:2356               \*\*            \-       

  IC3       EGR1                                                                                                Early growth response 1    350/493:2780    \*\*\*   \*\*\*

  VDR       Vitamin D (1,25- dihydroxyvitamin D3) receptor                                                      81/493:423                 \*\*\*          \*\*     

  ZNF263    Zinc finger protein 263                                                                             137/493:856                \*\*\*          \*       

  TFAP2C    TF AP-2 gamma (activating enhancer binding protein 2 gamma)                                         366/493:3187               \*\*\*          \-       

  CTCF      CCCTC-binding factor (zinc finger protein)                                                          409/493:3720               \*\*            \-       

  IC4       GATA2                                                                                               GATA binding protein 2     211/470:1547    \*\*\*   \-

  FOXA1     Forkhead box A1                                                                                     319/470:2685               \*\*\*          \-       

  GATA3     GATA binding protein 3                                                                              246/470:1981               \*\*\*          \*       

  SMARCA4   SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4   416/470:3859               \*\*\*          \-       

  SPI1      Spi-1 proto-oncogene                                                                                160/470:1190               \*\*\*          \*\*\*   

  TAL1      T-cell acute lymphocytic leukemia 1                                                                 121/470:864                \*\*\*          \-       

  TP53      Tumor protein p53                                                                                   80/470:548                 \*\*\*          \-       

  CEBPA     CCAAT/enhancer binding protein (C/EBP), alpha                                                       321/470:2904               \*\*            \*\*     

  STAT1     Signal transducer and activator of transcription 1, 91kDa                                           326/470:2972               \*\*            \*\*     

  CTCF      CCCTC-binding factor (zinc finger protein)                                                          392/470:3720               \*\*            \-       

  ESR1      Estrogen receptor 1                                                                                 193/470:1656               \*\*            \-       

  SOX2      SRY-box 2                                                                                           97/470:746                 \*\*            \-       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: TF, transcription factor

Discussion and conclusions {#sec021}
==========================

Previous studies have accumulated evidence about the health risk reduction as a result of moderate physical activity \[[@pone.0180322.ref001]\]. Nevertheless, an U-curve pattern has been previously described when considering the effect of high intensity and prolonged exercise over cardiovascular \[[@pone.0180322.ref003]\] or URTI \[[@pone.0180322.ref016]\] risks. In this sense, an UMT is of interest due to its extreme conditions \[[@pone.0180322.ref005]\] and its consequences on the whole body homeostasis. To our knowledge, the present study is the first genome-wide investigation aiming an expression profiling in response to a UMT race.

Our results show that gene expression is heavily impacted by the intervention based on the 5,084 protein-coding genes, among 23,557 initially tested, with significant differential expression. The global gene enrichment analysis reveals extensive alterations in human biology mainly concentrated around the immune system, infectious diseases and genetic information processing.

A 36% of the enriched infectious diseases terms ([Table 3](#pone.0180322.t003){ref-type="table"}) are caused by parasitic (*Toxoplasmosis*) and viral pathogens (*Epstein-Barr virus infection*, *Herpes simplex infection* and *Influenza A*) associated with URTI \[[@pone.0180322.ref062]\], An additional 27% implicates pathogens responsible of other respiratory infections such *Legionellosis*, *Measles* and *Tuberculosis*, the latter primarily attacking the lungs, while the rest were unrelated respiratory infections. These results do not necessarily imply that subjects presented a particular infection, but its genetic mechanisms triggered by the strenuous exercise.

We interpret protein synthesis as repressed based on the systematic down-regulation of the genes annotated to the related intracellular processes. This response is compatible with two opposite situations: the negative energy balance due to the high-demanding exercise \[[@pone.0180322.ref063]\] and, as defined by other authors, the maintenance of protein levels is a bioenergetically expensive process \[[@pone.0180322.ref064]\]. In a similar experiment using muscle biopsy samples, authors found an activation of muscle protein degradation in addition to muscle protein repression \[[@pone.0180322.ref065]\]. The autophagy-lysosomal and the ubiquitin proteasome pathways (UPP) mainly control protein degradation in skeletal muscle \[[@pone.0180322.ref066]\]. We report an overrepresentation of the *Lysosome* pathway with a general up-regulation of up to 65% of its annotated differential genes. Controversially, overrepresented pathways related to UPP clearly emerged down-regulated, *Ubiquitin mediated proteolysis* and *Proteasome*, with the 78% and 91% of their annotated differential genes respectively.

HIF-1 signalling pathway enrichment is aligned with the TREA results where EPAS1 (aka HIF-2α) and HIF-1A were found. We identified the up-regulation of genes related to the increase oxygen delivery (TIMP-1, HMOX-1), oxygen consumption reduction (HK, ALDOA and PFK2) and associated TR (HIF-1β aka ARNT). In human skeletal muscle studies, HIF-1 has been held to be responsible for, among other functions, a reduction in mitochondrial activity \[[@pone.0180322.ref020]\] and VEGF regulation \[[@pone.0180322.ref067]\]. Its activation has been previously reported after a single exercise \[[@pone.0180322.ref068]\]. On the other hand, the EPAS1 gene is a TF that plays a key role in the HIF pathway by activating genes in response to hypoxia \[[@pone.0180322.ref069]\], specifically those involved in erythropoiesis and angiogenesis \[[@pone.0180322.ref070]\]. While several studies have evaluated the influence of EPAS1 genetic variants in individual aerobic capacity \[[@pone.0180322.ref070]\] and athletic performance \[[@pone.0180322.ref071]\]; to our knowledge no specific studies have explored the EPAS1 response to exercise from a transcriptomics approach. Additionally, there is prior evidence of the collaboration of ETS1, another overrepresented TF, with HIF-1 in regulating hypoxia-inducible genes in pathological situations \[[@pone.0180322.ref072]\].

ICA identified further biological pathways including key alteration in mitochondrial activity and endocannabinoid signalling. Several genes from the ETC were systematically down-regulated as a obtained from the GEA applied to the ICs ([Table 10](#pone.0180322.t010){ref-type="table"}). Most of them (NDUFA9, NDUFAB1, CYC1, UQCRQ and ATP5A1) are reported as a direct effect of ETS1 in cancer cells in its role of mitochondrial stress and dysfunction regulation \[[@pone.0180322.ref073]\]. TP53 gene was one of the additional transcriptional regulators retrieved after applying ICA. TP53 stands as an stress sensor of the cell such as oxidative stress, hypoxia and nutrient depravation \[[@pone.0180322.ref074]\], signals compatible with the experiment. Additionally, the TP53 gene has been related to the regulation of mitochondrial respiration \[[@pone.0180322.ref075]\] and possible exercise-induced mitochondrial biogenesis \[[@pone.0180322.ref002],[@pone.0180322.ref076]\] through interactions with TFAM in the mitochondria. However, we have not observed any differential expression in TFAM. With regard to the endocannabinoid-signalling pathway, recent studies in mice describe the so called "runner's high" dependence on the endocannabinoid system in response to wheel running \[[@pone.0180322.ref077]\] and how this exercise-induced effect is intensity-modulated in humans \[[@pone.0180322.ref078],[@pone.0180322.ref079]\].

The current study has, however, certain limitations. First, the small sample size could limit the results validation in newer cohorts. However, the findings are consistent with existing literature in exercise-related studies. Secondly, the physical effort of each runner may be heterogeneous for the same completed distance. Nevertheless, this feature may be difficult to include in the linear regression model beyond the runner's subjective perception.

In conclusion, the present study points to almost one fourth of all protein-coding genes affected by running an UMT, with a substantial number of human biology pathways overrepresented. In agreement with prior exercise-related studies, the global physiological approach is predominantly associated with immune system, infectious diseases and genetic information processing. The independent activity approach revealed additional pathways beyond the abovementioned which will require tailored investigations in larger sample sizes. Biological pathways and transcriptional regulators overrepresentation analysis offered a complementary interpretation of the results.
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